Author: Bambusa Therapeutics

Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential

July 27, 2026
Bambusa Therapeutics Appoints Howard Liang, Ph.D. to its Board of Directors and Establishes Scientific Advisory Board

July 15, 2026

Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential